ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Therapeutic Targeting of Bile Acid Metabolism Ameliorates Liver Ischemia/Reperfusion Injury

M. Ni1, D. Jin2, T. Lu2, J. Zhang1, R. Busuttil1, J. Kupiec-Weglinski1, J. Zhang2, Y. Zhai1

1Dumont-UCLA Transplant Center, Los Angeles, CA, 2Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Meeting: 2020 American Transplant Congress

Abstract number: 595

Keywords: Ischemia, Liver metabolism, Liver preservation, Liver transplantation

Session Information

Session Name: All Organs: Organ Preservation/Ischemia Reperfusion Injury

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

*Purpose: Farnesoid X receptor (FXR) is the major nuclear receptor of bile acids, which is also involved in the regulation of innate immune responses. As livers express high levels of FXR, we explored the potential therapeutic benefits and underlying mechanisms of pharmacological FXR activation in liver ischemia and reperfusion injury.

*Methods: In a murine liver partial warm ischemia model (60m and 90m), we treated mice with FXR agonist 3-(2,6-dichlorophenyl)-4-(3′-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (GW4064) or obeticholic acid (OCA) either 1h prior to the onset of ischemia (pretreatment, 1 dose) or starting at 24h post reperfusion (posttreatment 1 dose/day x3) to determine its effect on the activation or the resolution of liver IRI, respectively.

*Results: Pretreatment of mice with FXR agonists attenuated liver IRI and inhibited pro-inflammatory response in wild-type but not FXR knockout mice at 6h post reperfusion: the serum ALT levels and liver pro-inflammatory gene expressions were decreased with better preserved liver architectures (lower Suzuki scores in H/E staining). Posttreatment with GW4064 facilitated liver recovery from IRI (hepatocellular damages were fully repaired at day 5 vs. day 7 in controls) by inhibiting inflammatory and enhancing reparative gene (MerTK, TIM-4) expressions. Mechanistically, Kupffer cells (KCs), rather than bone marrow-derived macrophages (BMMs), expressed functional FXR. Pretreatment of KCs, but not BMMs, with GW4064 resulted in lower tumor necrosis factor-α but higher interleukin-10 productions upon toll-like receptor stimulation. FXR-targeted gene small heterodimer partner (SHP) was critical for the regulation of KC response by GW4064. as its knockdown by its specific siRNA diminished the immune regulatory effect of FXR activation. In vivo, the depletion of KCs (by clodronate encapsulated liposomes), but not infiltrating macrophages (CD11b+ by diphtheria toxin in CD11b-DTR mice), or knockdown of SHP (i.v. injection of its siRNA carried by mannose-conjugated polymers) abrogated the immune regulatory and cytoprotective effect of GW4064 in liver IRI.

*Conclusions: Phamacological activation of FXR protects livers from IRI by up-regulating SHP in KCs to inhibit liver proinflammatory response.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ni M, Jin D, Lu T, Zhang J, Busuttil R, Kupiec-Weglinski J, Zhang J, Zhai Y. Therapeutic Targeting of Bile Acid Metabolism Ameliorates Liver Ischemia/Reperfusion Injury [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/therapeutic-targeting-of-bile-acid-metabolism-ameliorates-liver-ischemia-reperfusion-injury/. Accessed May 16, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences